The Genitourinary Cancers Program is composed of 33 investigators (29 Full and 4 Associate members) from 13 Departments. The Program consists of a group of basic and clinical investigators collectively focused upon the study and treatment of GU malignancies.
The specific aims of this Program are to: 1) Understandfundamental mechanisms that contribute to development and progression of prostate and bladder cancer; and 2) Support and advance the development of clinicians and research scientists working in a collaborative manner on GU cancers to establish novel basic, translational and clinical research programs. There are two major areas of research focus within the GU Cancer Program: prostate cancer and bladder cancer. The GU Program has developed funded research and clinical programs focused on androgen receptor (AR) signaling in prostate cancer, prostate cancer stem cells, imaging, diagnosis and focal therapy of early stage prostate cancers, as well as urothelial carcinogenesis. Utilizing these strengths, the current focus has expanded into imaging, focal therapy, molecular risk stratification, stem cell biology/etiology, and a population-based approach to racial disparity in prostate cancer. Drs. Michael Garabedian and Samir Taneja are the Co-Leaders for this Program. Total funding increased from $3,497,189 to $5,888,351 since the last competitive application. Membership has increased from 27 to 33. Publications for the period total 245, of which 26.9% are intra-programmatic, 12.2% are inter-programmatic, and 8.2% are both intra- and inter-programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016087-33
Application #
8436437
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-03-01
Project End
2018-02-28
Budget Start
2013-04-01
Budget End
2014-02-28
Support Year
33
Fiscal Year
2013
Total Cost
$23,356
Indirect Cost
$9,577
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Kim, Sungheon G; Feng, Li; Grimm, Robert et al. (2016) Influence of temporal regularization and radial undersampling factor on compressed sensing reconstruction in dynamic contrast enhanced MRI of the breast. J Magn Reson Imaging 43:261-9
Zakhar, Joseph; Amrock, Stephen M; Weitzman, Michael (2016) Passive and Active Tobacco Exposure and Children's Lipid Profiles. Nicotine Tob Res 18:982-7
Pham, Alissa M; Santa Maria, Felicia Gilfoy; Lahiri, Tanaya et al. (2016) PKR Transduces MDA5-Dependent Signals for Type I IFN Induction. PLoS Pathog 12:e1005489
Pylayeva-Gupta, Yuliya; Das, Shipra; Handler, Jesse S et al. (2016) IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. Cancer Discov 6:247-55
Lau, Colleen M; Nish, Simone A; Yogev, Nir et al. (2016) Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses. J Exp Med 213:415-31
Vogelsang, Matjaz; Martinez, Carlos N; Rendleman, Justin et al. (2016) The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis. Clin Cancer Res 22:3268-80
Domènech-Estévez, Enric; Baloui, Hasna; Meng, Xiaosong et al. (2016) Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS. J Neurosci 36:4506-21
Abdu, Yusuff; Maniscalco, Chelsea; Heddleston, John M et al. (2016) Developmentally programmed germ cell remodelling by endodermal cell cannibalism. Nat Cell Biol 18:1302-1310
Reynaud, Olivier; Winters, Kerryanne Veronica; Hoang, Dung Minh et al. (2016) Pulsed and oscillating gradient MRI for assessment of cell size and extracellular space (POMACE) in mouse gliomas. NMR Biomed 29:1350-63
Sun, Xiaoqiang; Bao, Jiguang; Shao, Yongzhao (2016) Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Sci Rep 6:22498

Showing the most recent 10 out of 878 publications